FDA Approves Ribociclib as a First Treatment Option for Metastatic Hormone Receptor-Positive Breast Cancer (UPDATED)
On March 13, the U.S. Food and Drug Administration (FDA) approved ribociclib as a first treatment option for hormone receptor-positive, HER2-negative metastatic breast cancer, when given with an aromatase inhibitor. Ribociclib will be sold under the brand name Kisqali by the pharmaceutical company Novartis.
UPDATE: On May 8, 2017, Novartis announced it received FDA approval for a Kisqali Femara Co-Pack. This will allow people to use one prescription to get 28 days’ worth of ribociclib and of the aromatase inhibitor letrozole (Femara) in one package, with one copay. The Kisqali Femara Co-Pack is available at the same cost as ribociclib alone, according to a Novartis press release.
“This is the first, and only currently available, combination pack with two prescription products in advanced breast cancer,” says the press release.
Doctors can still choose to give ribociclib in combination with an aromatase inhibitor other than letrozole. When taking it with a different aromatase inhibitor, you will need a separate prescription for each medicine, and will likely need to pay a copay for each one.
Ribociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor. Cyclin-dependent kinases 4 and 6 are two proteins that cause tumor cells in some breast cancers to grow. CDK 4/6 inhibitors like ribociclib work by blocking CDK 4 and 6 from telling cancer cells to multiply. This can slow the growth or spread of cancer cells.
Ribociclib is only the second CDK 4/6 inhibitor to be FDA-approved. The other is palbociclib (Ibrance).
Ribociclib was granted breakthrough therapy designation by the FDA in August 2016. This status can be given to medicines that are intended to treat a serious illness, like metastatic cancer, if early clinical trials suggest the medicine works considerably better than existing therapies.
When a medicine gets breakthrough therapy designation, the FDA speeds up its normal review process. This way, if the medicine does get FDA approval, it can be made available to the public as soon as possible.
The MONALEESA-2 Trial
Ribociclib was approved based on results from the phase III MONALEESA-2 trial, which LBBC reported on in November 2016. Researchers found that postmenopausal women who took ribociclib and letrozole had longer periods of progression-free survival than those who took a placebo and letrozole. They found that 18 months after entering the study, the disease hadn’t progressed in
- 63 percent of participants taking letrozole with ribociclib
- 42 percent of participants taking letrozole with a placebo
What This Means for You
Metastatic breast cancer is a disease you will have to treat for the rest of your life. Getting treatments to work longer means more time when the cancer isn’t growing and more time without having to switch to other medicines and experience new side effects.
Up until now, ribociclib has mostly only been available through clinical trials. Now that the FDA has approved it, ribociclib will be widely available.
Ribociclib and palbociclib seem quite similar, says Kathy D. Miller, MD, an associate professor and Sheila D. Ward Scholar at Indiana University and a member of LBBC’s Medical Advisory Board, but they haven’t been directly compared to each other in a trial. There is no reason for people who are doing well on palbociclib to switch to ribociclib, Dr. Miller says. Doctors don’t yet know if ribociclib will work if treatment with palbociclib stops working, or if palbociclib will work if treatment with ribociclib stops working.
Talk to your doctor about whether a CDK 4/6 inhibitor is a good treatment option for you, and about whether ribociclib or palbociclib would be best.